Date: 2014-08-26
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9 in Washington
Company: Cubist Pharmaceuticals (USA - MA)
Product: ceftolozane/tazobactam
Action mechanism:
Disease:
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On August 26, 2014, Cubist Pharmaceuticals announced that it will present new data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9 in Washington. Noteworthy presentations will include data on the investigational antibiotic ceftolozane/tazobactam. Ceftolozane/tazobactam is under review by the FDA for the treatment of complicated urinary tract infections and complicated intra-abdominal infections and has an FDA action date of December 21, 2014. Poster:Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Pseudomonas aeruginosa isolates from United States medical centers (2013). Poster C-771. Presenter: David J. Farrell, JMI Lab., North Liberty, IA Poster: Susceptibility profile of commonly utilized parenteral antimicrobials against E. coli, K. pneumoniae and P. aeruginosa from US hospitals. Poster C-119. Presenter: Christina A. Sutherland, Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut Poster: Activity of ceftolozane/tazobactam against isolates of Enterobacteriaceae and P. aeruginosa from US hospitals testing non-susceptible to piperacillin/tazobactam. Poster C-770. Presenter: Christina A. Sutherland, Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut Poster:Epidemiology and susceptibility of organisms isolated from patients with cIAI: results from ASPECT?cIAI. Poster C-774. Presenter: E.S. Armstrong, Cubist Pharmaceuticals Poster:Epidemiology and susceptibility of organisms isolated from patients With cUTI: results from ASPECT?cUTI. Poster C-127. Presenter: E.S. Armstrong, Cubist Pharmaceuticals.
